文献速递主动脉疾病内脏/肾动脉与血管畸形

新型血流动力学密网支架治疗Stanford A型或B型主动脉夹层近端修复后残余夹层的早期结果:多中心前瞻性随机研究单中心初步报告

Early Results of the Newly-Designed Flowdynamics Dense Mesh Stent for Residual Dissection After Proximal Repair of Stanford Type A or Type B Aortic Dissection: A Preliminary Single-Center Report From a Multicenter, Prospective, and Randomized Study.
PubMed 文献 · J Endovasc Ther · 2023-03-28

本单中心报告来自多中心前瞻性随机对照研究,纳入36例非慢性残余夹层累及内脏分支患者,随机分入血流动力学密网支架(FDMS)组与对照组。12个月随访显示全因死亡免除率94.4%、主动脉相关死亡免除率100%,FDMS组内脏分支均保持通畅,真腔面积增加、假腔面积减小。作者认为FDMS在近端修复后残余夹层的腔内治疗中于12个月时安全有效。

要点

  • 36例患者中34例完成12个月随访,全因死亡免除率94.4%、主动脉相关死亡免除率100%。
  • FDMS组所有内脏分支均保持通畅。
  • FDMS组真腔面积增加、假腔面积减小,与对照组相比有显著差异。

核心结论

  • 作者认为,新型FDMS用于近端修复后残余夹层的腔内治疗在12个月时安全有效。
  • 临床影响部分指出,该随机对照试验的1年结果提示FDMS治疗近端修复后非慢性残余夹层具有短期安全性和良好效果。

研究设计与样本

  • 多中心、前瞻性、随机对照研究(ChiCTR1900023638),本报告为其中单中心初步经验。
  • 本中心共纳入36例非慢性残余夹层累及内脏分支患者,随机分入FDMS组和对照组。
  • 招募后1、3、6、12个月安排随访;主要终点为全因死亡和主动脉相关死亡,次要终点包括内脏分支闭塞、再干预和严重不良事件。

主要发现

  • 34例患者完成12个月随访,全因死亡免除率为94.4%,主动脉相关死亡免除率为100%。
  • FDMS组所有内脏分支均保持通畅。
  • 肾动脉下平面真腔面积增加:FDMS组1.03±0.38 cm2 vs 对照组0.48±0.63 cm2,p=0.006。
  • 肾动脉下5 cm平面真腔面积增加:FDMS组1.27±0.80 cm2 vs 对照组0.32±0.50 cm2,p<0.001。
  • 肾动脉下平面假腔面积减小:FDMS组-1.03±0.84 cm2 vs 对照组-0.15±1.21 cm2,p=0.023;FDMS组真腔体积显著增加(p<0.001)、假腔体积显著减小(p=0.018)。

临床怎么用

  • 作者认为,FDMS可用于近端修复后非慢性残余夹层的腔内治疗,12个月时安全有效。
  • 临床影响部分指出,该结果据作者所知是首个关于多层血流网支架治疗主动脉夹层的随机对照研究,有望为临床实践提供高质量证据并填补FDMS应用空白。

局限性

  • 本文为初步单中心报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Negative remodeling of the distal aorta due to residual dissection significantly impacts the long-term outcomes of dissection patients after proximal repair of acute aortic dissection. Branched/fenestrated aortic stents are technically demanding, and studies of the first generation of multilayer flow modulators for tackling this clinical scenario are few and limited. The single-center results from a multicenter, prospective, and randomized controlled study aimed to verify the safety and effectiveness of a newly-designed flowdynamics dense mesh stent for treating residual dissection after proximal repair. METHODS: Patients with nonchronic residual dissection involving visceral branches were prospectively enrolled in 3 centers (ChiCTR1900023638). Eligible patients were randomly assigned to the flowdynamics dense mesh stent (FDMS) group and control group. Follow-up visits were arranged at 1, 3, 6, and 12 months after recruitment. The primary endpoints were all-cause and aortic-related mortality. The secondary endpoints included visceral branch occlusion, reintervention, and severe adverse events. Morphological changes were analyzed to exhibit the therapeutic effect. Our center participated in the multicenter prospective randomized controlled trial, and the preliminary single-center experience was reported. RESULTS: Thirty-six patients were enrolled in our center, and the baseline characteristics of the 2 groups were comparable. Thirty-four patients completed the 12 month follow-up. Freedom from all-cause and aortic-related death were 94.4% and 100%. All visceral branches remained patent in the FDMS group. Increased area of the true lumen (1.03±0.38 vs 0.48±0.63 cm2 at the plane below renal arteries, p=0.006; 1.27±0.80 vs 0.32±0.50 cm2 at the plane 5 cm below renal arteries, p<0.001) and decreased area of the false lumen at the plane below renal arteries (-1.03±0.84 vs -0.15±1.21 cm2, p=0.023) were observed in the FDMS group compared with those parameters in the control group. The FDMS group showed a significant increase in true lumen volume (p<0.001) and a significant decrease in false lumen volume (p=0.018). CONCLUSIONS: This newly-designed FDMS for endovascular repair of residual dissection after the proximal repair is safe and effective at 12 months. CLINICAL IMPACT: One-year results of the randomized controlled clinical trial indicated the short-term safety and promising effect of FDMS on treating non-chronic residual dissection after proximal repair. At the 12th-month follow-up, the true lumen expanded, the false lumen shrunk and all visceral arteries kept patent. As far as I'm concerned, this is the first randomized controlled study concerning utilizing multilayer flow mesh stent treating aortic dissection. Despite a preliminary single-center report, our results are supposed to provide high-quality evidence to guide clinical practice and fill the gap in the application of FDMS.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Lu C, Wang H, Yang P, et al. Early Results of the Newly-Designed Flowdynamics Dense Mesh Stent for Residual Dissection After Proximal Repair of Stanford Type A or Type B Aortic Dissection: A Preliminary Single-Center Report From a Multicenter, Prospective, and Randomized Study. J Endovasc Ther. 2023. PMID: 36978288. doi:10.1177/15266028231163057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。